About This Article
To compare the pharmacokinetic (PK) [area under the curve (AUC0–24 h, Cmax)] and pharmacodynamic (PD) (AUCGIR 0–24 h, GIRmax) properties of single-dose insulin detemir in the presence or absence of steady-state liraglutide (1.8 mg dose) in subjects with type 2 diabetes to determine whether co-administration affected the PK and PD profiles of either therapeutic agent.